Abstract
In adult rat ventricular cardiomyocytes, noradrenaline exerts dual effects on protein synthesis: increases via α1-adrenoceptors and decreases via β1-adrenoceptors. Carvedilol and bucindolol are β-blockers with additional α1-adrenoceptor blocking activities. We studied the effects of carvedilol and bucindolol on noradrenaline-induced protein synthesis (assessed by [3H]phenylalanine incorporation) in adult rat ventricular cardiomyocytes. Radioligand binding studies with [125I]iodocyanopindolol and [3H]prazosin revealed that carvedilol had a much higher affinity to α1-adrenoceptors than bucindolol (β1-/α1-adrenoceptor ratio for carvedilol, 1:2.7; for bucindolol, 1:43). Noradrenaline-evoked increases in protein synthesis were enhanced by propranolol (1 μM) and β1-adrenoceptor-selective antagonists bisoprolol (1 μM) and CGP 20712A [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)-ethyl-amino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propranol methanesulfonate] (300 nM). Carvedilol (100 pM–10 μM) inhibited 1 μM noradrenaline-induced increase in protein synthesis with monophasic concentration-inhibition curves independent of whether CGP 20712A was present or not; Ki values for carvedilol were 5 to 6 nM. In contrast, bucindolol (100 pM–10 μM) inhibited l μM noradrenaline-induced increase in protein synthesis with a bell-shaped concentration-inhibition curve; it increased noradrenaline-induced protein synthesis at 10 nM, although at concentrations >100 nM it was inhibited. In the presence of 300 nM CGP 20712A or 1 μM propranolol, however, bucindolol inhibited 1 μM noradrenaline-induced increase in protein synthesis with monophasic concentration-inhibition curves; Ki values were 40 to 75 nM. On the other hand, both carvedilol and bucindolol inhibited 1 μM phenylephrine-induced protein synthesis with monophasic concentration-inhibition curves;Ki values were 4 (carvedilol) and 45 nM (bucindolol). These results indicate that, at low (β-adrenoceptor blocking) concentrations, bucindolol can enhance noradrenaline-induced protein synthesis whereas it is inhibited by carvedilol.
Footnotes
-
This work was supported by grants from the Deutsche Forschungsgemeinschaft (Bonn, Germany; SFB TR 2-01) and by GlaxoSmithKline Pharmaceuticals (King of Prussia, PA).
- Abbreviations:
- CGP 20712A
- 1-[2-((3-carbamoyl-4-hydroxy)phenoxy)-ethyl-amino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propranol methanesulfonate
- CGP 12177
- 4-(3′-tert-butylamino-2′-hydroxypropoxy)-benzimidazole-2 hydrochloride
- NA
- noradrenaline
- PE
- phenylephrine
- ICI 118,551
- (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[1-methylethyl)amino]-2-butanol hydrochloride
- Received July 25, 2001.
- Accepted December 5, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|